›› 2018, Vol. 36 ›› Issue (5): 389-.doi: 10.3969/j.issn.1000-3606.2018.05.017
Previous Articles Next Articles
Reviewer:ZHAO Jie,LI Benshang, Reviser:TANG Jingyan
Received:
Online:
Published:
Abstract: Neuroblastoma is the most common extra-cranial malignant tumor in childhood. About 50% of the children have widespread metastatic diseases at initial diagnosis and the outcomes are poor. Chimeric antigen receptor (CAR) is a kind of genetically engineered receptors usually generated by extracellular antigen recognition region, spacer, transmembrane domain and intracellular endodomain. The antigen recognition region joining heavy and light chain variable regions of a monoclonal antibody with a linker to form a single-chain variable fragment (scFv) which can bind to tumor-associated antigens and lead to anti-tumor activity in an MHC-unrestricted manner. In this review, the recent advances and applications of CAR-T cell in neuroblostoma are reviewed and the application-related problems and possible solving strategies are discussed.
ZHAO Jie,LI Benshang. Advances in neuroblastoma immunotherapy based on chimeric antigen receptor[J]., 2018, 36(5): 389-.
0 / / Recommend
Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks
URL: https://jcp.xinhuamed.com.cn/EN/10.3969/j.issn.1000-3606.2018.05.017
https://jcp.xinhuamed.com.cn/EN/Y2018/V36/I5/389
Cited